The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...

AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...